中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2008年
4期
242-245
,共4页
王君平%孙殿兴%李兵顺%康富标%李敏然%郭争荣%亢继文%李伟勇
王君平%孫殿興%李兵順%康富標%李敏然%郭爭榮%亢繼文%李偉勇
왕군평%손전흥%리병순%강부표%리민연%곽쟁영%항계문%리위용
肝硬化%粒细胞集落刺激因子%干细胞
肝硬化%粒細胞集落刺激因子%榦細胞
간경화%립세포집락자격인자%간세포
Liver cirrhosis%Granulocyte colony stimulating factor%Stem cells
目的 观察重组人粒细胞集落刺激因子(rhG-CSF)对四氯化碳(CCl4)所致小鼠慢性肝损伤的治疗作用.方法 清洁级雄性BALB/C小鼠分为治疗组与对照组.每周2次CCl4腹腔注射制备慢性肝损伤模型.造模成功后治疗组给予rhG-CSF(200 μg·kg-1·d-1)皮下注射7 d,对照组给予同等剂量0.9%氯化钠溶液.测定小鼠体质量、肝重和脾重.采用临床常规方法检测肝功能、肝纤维化指标.对肝纤维化程度进行评分.流式细胞仪计数分析肝组织中CD34+细胞,免疫组化法测定Thy-1+表达.结果 治疗组小鼠第8和15天时脾重与肝重比值(15.94%±1.20%和10.52%±0.66%)与对照组(7.14%±1.68%和8.31%±1.71%)比较差异有统计学意义(P值均＜0.05),两组小鼠体质量和肝重差异无统计学意义(P＞0.05).第15天时治疗组小鼠白蛋白水平快速上升.第30天时治疗组丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、透明质酸(HA)、层粘连蛋白(LN)水平均低于对照组.第30天时两组肝纤维化程度计分差异有统计学意义(治疗组5.49±2.16,对照组8.74±1.86,P＜0.05).治疗组小鼠肝脏组织中CD34+细胞和Thy-1+阳性细胞数在第8天(9.54±2.24和5.10±1.25)和第15天(8.18±1.93和7.53±1.39)时高于对照组(第8天时5.40±0.99和3.25±0.75;第15天时4.46±0.77和3.35±0.86,P值均＜0.05).结论 rhG-CSF能促进慢性肝损伤的恢复,将为肝纤维化提供一个新的治疗方法.
目的 觀察重組人粒細胞集落刺激因子(rhG-CSF)對四氯化碳(CCl4)所緻小鼠慢性肝損傷的治療作用.方法 清潔級雄性BALB/C小鼠分為治療組與對照組.每週2次CCl4腹腔註射製備慢性肝損傷模型.造模成功後治療組給予rhG-CSF(200 μg·kg-1·d-1)皮下註射7 d,對照組給予同等劑量0.9%氯化鈉溶液.測定小鼠體質量、肝重和脾重.採用臨床常規方法檢測肝功能、肝纖維化指標.對肝纖維化程度進行評分.流式細胞儀計數分析肝組織中CD34+細胞,免疫組化法測定Thy-1+錶達.結果 治療組小鼠第8和15天時脾重與肝重比值(15.94%±1.20%和10.52%±0.66%)與對照組(7.14%±1.68%和8.31%±1.71%)比較差異有統計學意義(P值均＜0.05),兩組小鼠體質量和肝重差異無統計學意義(P＞0.05).第15天時治療組小鼠白蛋白水平快速上升.第30天時治療組丙氨痠轉氨酶(ALT)、天鼕氨痠轉氨酶(AST)、透明質痠(HA)、層粘連蛋白(LN)水平均低于對照組.第30天時兩組肝纖維化程度計分差異有統計學意義(治療組5.49±2.16,對照組8.74±1.86,P＜0.05).治療組小鼠肝髒組織中CD34+細胞和Thy-1+暘性細胞數在第8天(9.54±2.24和5.10±1.25)和第15天(8.18±1.93和7.53±1.39)時高于對照組(第8天時5.40±0.99和3.25±0.75;第15天時4.46±0.77和3.35±0.86,P值均＜0.05).結論 rhG-CSF能促進慢性肝損傷的恢複,將為肝纖維化提供一箇新的治療方法.
목적 관찰중조인립세포집락자격인자(rhG-CSF)대사록화탄(CCl4)소치소서만성간손상적치료작용.방법 청길급웅성BALB/C소서분위치료조여대조조.매주2차CCl4복강주사제비만성간손상모형.조모성공후치료조급여rhG-CSF(200 μg·kg-1·d-1)피하주사7 d,대조조급여동등제량0.9%록화납용액.측정소서체질량、간중화비중.채용림상상규방법검측간공능、간섬유화지표.대간섬유화정도진행평분.류식세포의계수분석간조직중CD34+세포,면역조화법측정Thy-1+표체.결과 치료조소서제8화15천시비중여간중비치(15.94%±1.20%화10.52%±0.66%)여대조조(7.14%±1.68%화8.31%±1.71%)비교차이유통계학의의(P치균＜0.05),량조소서체질량화간중차이무통계학의의(P＞0.05).제15천시치료조소서백단백수평쾌속상승.제30천시치료조병안산전안매(ALT)、천동안산전안매(AST)、투명질산(HA)、층점련단백(LN)수평균저우대조조.제30천시량조간섬유화정도계분차이유통계학의의(치료조5.49±2.16,대조조8.74±1.86,P＜0.05).치료조소서간장조직중CD34+세포화Thy-1+양성세포수재제8천(9.54±2.24화5.10±1.25)화제15천(8.18±1.93화7.53±1.39)시고우대조조(제8천시5.40±0.99화3.25±0.75;제15천시4.46±0.77화3.35±0.86,P치균＜0.05).결론 rhG-CSF능촉진만성간손상적회복,장위간섬유화제공일개신적치료방법.
Objective To observe the therapeutic effects of recombinant human granulocyte colony stimulating factor(rhG-CSF)on CCl4 induced chronic liver injury.Methods Male BALB/C mice were randomly allocated into treatment and control groups.The mice model were established by injection with daily for 7 days,while the control mice were received the same volumes of saline.The mice were sacrificed to get weight,liver mass and spleen mass.The count of CD34+ cells and Thy-1+ cells were analyzed by flow cytometry and immunohistochemical staining,respectively.Results The ratio of liver/spleen was 15.94±1.20 and 10.52±0.66 on day 8 and 15 in treatment group,respectively,while those were 7.14±1.68 and 8.31±1.71 in control group,respectively(all P value＜0.05).But there was no significant difference in body weight and liver mass between two groups(P＞0.05)The concentration of album in treatment group was raised rapidly on day 15.The concentrations of alanine aminotransferase (ALT),aspartate aminotransferase(AST),hyaluronic acid(HA)and laminin(LN)on day 30 were significantly lower in treatment group compared to control group(P＜0.05).There was significant difference in score of liver fibrosis on day 30 between two groups(treatment group:5.49±2.16,control:8.74±1.86,P＜0.05).The number of CD34+ cell and Thy-1+ in treatment group(on day 8:9.54±2.24 and 5.10±1.25 and on day 15:8.18±1.93 and 7.53±1.39,respectively)were higher than those in control group(on day 8:5.40±0.99 and 3.25±0.75;on 15 days:4.46±0.77 and 3.35±0.86,all P value＜0.05).Conclusion The rhG-CSF may improve the reparation of chronic liver injury,and may provide a novel method in treatment of liver fibrosis.
